Program
CT-202
A development code.
Its studies are mostly in Triple Negative Breast Neoplasms, led by Context Therapeutics.
Furthest: phase 1, since Apr 16, 20261 company-led study, 1 open or runningNext primary completion: Jan 2030 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Context Therapeutics | 11 open or running | phase 1since Apr 16, 2026 | Apr 16, 2026 | Jan 2030phase 1 · NCT07545122 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2026First study: phase 1 study in Triple Negative Breast NeoplasmsFirst studyNCT07545122 · 162 planned · Australia
Ahead
- Jan 2030Primary completion: phase 1 study in Triple Negative Breast NeoplasmsNCT07545122
TargetBeta
NECTIN4 →read by rule
“A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, and Urothelial Cancers”study text, by rule · the study
Other programs on NECTIN4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enfortumab vedotinrule | Astellas Pharma | phase 4 | 20 |
| notiretatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 14 |
| bulumtatug fuvedotinrule | Mabwell (Shanghai) Bioscience | phase 3 | 13 |
| Sutantatug Envedotinrule | CSPC Pharmaceutical Group | phase 3 | 6 |
| zelenectide pevedotinrule | bicycletx-limited | phase 2 | 5 |
| Anti-nectin-4 Antibody-drug Conjugate MK-3120rule | Merck | phase 2 | 5 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-nectin-4 Antibody-drug Conjugate IPH4502rule | innate-pharma | phase 1 | 1 |
| Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rule | rondo-therapeutics | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07545122Triple Negative Breast Neoplasms · Australia | 1 | Recruiting | Jan 2030 | 162 |
How it is read
Names in the registry
- “CT-202”, 1 entry
Codes read as this program: CT202.
Conditions, from the studies’ own filings
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.